TY - JOUR AU - Kobayashi, N. AU - Iijima, H. AU - Tada, T. AU - Kumada, T. AU - Yoshida, M. AU - Aoki, T. PY - 2018 DA - 2018// TI - Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response JO - Eur J Gastroenterol Hepatol VL - 30 UR - https://doi.org/10.1097/MEG.0000000000001106 DO - 10.1097/MEG.0000000000001106 ID - Kobayashi2018 ER - TY - JOUR AU - Tada, T. AU - Kumada, T. AU - Toyoda, H. AU - Sone, Y. AU - Takeshima, K. AU - Ogawa, S. PY - 2018 DA - 2018// TI - Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy JO - Aliment Pharmacol Ther VL - 47 UR - https://doi.org/10.1111/apt.14554 DO - 10.1111/apt.14554 ID - Tada2018 ER - TY - JOUR AU - Trivedi, H. D. AU - Lin, S. C. AU - TY Lau, D. PY - 2017 DA - 2017// TI - Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders JO - Gastroenterol Hepatol VL - 13 ID - Trivedi2017 ER - TY - JOUR AU - Kozbial, K. a. r. i. n. AU - Moser, S. t. e. p. h. a. n. AU - Al-Zoairy, R. a. m. o. n. a. AU - Schwarzer, R. e. m. y. AU - Datz, C. h. r. i. s. t. i. a. n. AU - Stauber, R. u. d. o. l. f. AU - Laferl, H. e. r. m. a. n. n. AU - Strasser, M. i. c. h. a. e. l. AU - Beinhardt, S. a. n. d. r. a. AU - Stättermayer, A. l. b. e. r. t. F. AU - Gschwantler, M. i. c. h. a. e. l. AU - Zoller, H. e. i. n. z. AU - Maieron, A. n. d. r. e. a. s. AU - Graziadei, I. v. o. AU - Trauner, M. i. c. h. a. e. l. AU - Steindl-Munda, P. e. t. r. a. AU - Hofer, H. a. r. a. l. d. AU - Ferenci, P. e. t. e. r. PY - 2017 DA - 2017// TI - Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment JO - Liver International VL - 38 UR - https://doi.org/10.1111/liv.13629 DO - 10.1111/liv.13629 ID - Kozbial2017 ER - TY - JOUR AU - Bartlett, S. R. AU - Grebely, J. AU - Eltahla, A. A. AU - Reeves, J. D. AU - Howe, A. Y. M. AU - Miller, V. PY - 2017 DA - 2017// TI - Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: a systematic review JO - Hepatol Commun VL - 22 UR - https://doi.org/10.1002/hep4.1050 DO - 10.1002/hep4.1050 ID - Bartlett2017 ER - TY - JOUR AU - Kjellin, M. AU - Wesslén, T. AU - Löfblad, E. AU - Lennerstrand, J. AU - Lannergård, A. PY - 2018 DA - 2018// TI - The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort JO - Ups J Med Sci VL - 123 UR - https://doi.org/10.1080/03009734.2018.1441928 DO - 10.1080/03009734.2018.1441928 ID - Kjellin2018 ER - TY - JOUR AU - Wang, G. P. AU - Terrault, N. AU - Reeves, J. D. AU - Liu, L. AU - Li, E. AU - Zhao, L. PY - 2018 DA - 2018// TI - Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection JO - Sci Rep VL - 8 UR - https://doi.org/10.1038/s41598-018-21303-2 DO - 10.1038/s41598-018-21303-2 ID - Wang2018 ER - TY - STD TI - European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. 2015. J Hepatol. 2015;63:199–236. ID - ref8 ER - TY - JOUR PY - 2015 DA - 2015// TI - AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus JO - HEPATOLOGY VL - 62 UR - https://doi.org/10.1002/hep.27950 DO - 10.1002/hep.27950 ID - ref9 ER - TY - JOUR AU - Afdhal, N. AU - Reddy, K. R. AU - Nelson, D. R. AU - Lawitz, E. AU - Gordon, S. C. AU - Schiff, E. PY - 2014 DA - 2014// TI - Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1316366 DO - 10.1056/NEJMoa1316366 ID - Afdhal2014 ER - TY - JOUR AU - Bourlière, M. AU - Bronowicki, J. P. AU - de Ledinghen, V. AU - Hézode, C. AU - Zoulim, F. AU - Mathurin, P. PY - 2015 DA - 2015// TI - Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(15)70050-2 DO - 10.1016/S1473-3099(15)70050-2 ID - Bourlière2015 ER - TY - JOUR AU - Lawitz, E. AU - Poordad, F. F. AU - Pang, P. S. AU - Hyland, R. H. AU - Ding, X. AU - Mo, H. PY - 2014 DA - 2014// TI - Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial JO - Lancet VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)62121-2 DO - 10.1016/S0140-6736(13)62121-2 ID - Lawitz2014 ER - TY - JOUR AU - Sulkowski, M. S. AU - Gardiner, D. F. AU - Rodriguez-Torres, M. AU - Reddy, K. R. AU - Hassanein, T. AU - Jacobson, I. PY - 2014 DA - 2014// TI - Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1306218 DO - 10.1056/NEJMoa1306218 ID - Sulkowski2014 ER - TY - JOUR AU - Flisiak, R. AU - Janczewska, E. AU - Wawrzynowicz-Syczewska, M. AU - Jaroszewicz, J. AU - Zarębska-Michaluk, D. AU - Nazzal, K. PY - 2016 DA - 2016// TI - Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study JO - Aliment Pharmacol Ther VL - 44 UR - https://doi.org/10.1111/apt.13790 DO - 10.1111/apt.13790 ID - Flisiak2016 ER - TY - JOUR AU - Halota, W. AU - Flisiak, R. AU - Boroń-Kaczmarska, A. AU - Juszczyk, J. AU - Małkowski, P. AU - Pawłowska, M. PY - 2016 DA - 2016// TI - Recommendations for the treatment of hepatitis C issued by the polish group of HCV experts – 2016 JO - Clin Exp Hepatol. VL - 2 UR - https://doi.org/10.5114/ceh.2016.59099 DO - 10.5114/ceh.2016.59099 ID - Halota2016 ER - TY - JOUR AU - Flisiak, R. AU - Pogorzelska, J. AU - Berak, H. AU - Horban, A. AU - Orłowska, I. AU - Simon, K. PY - 2016 DA - 2016// TI - Prevalence of HCV genotypes in Poland - the EpiTer study JO - Clin Exp Hepatol. VL - 2 UR - https://doi.org/10.5114/ceh.2016.63871 DO - 10.5114/ceh.2016.63871 ID - Flisiak2016 ER - TY - JOUR AU - Halota, W. AU - Flisiak, R. AU - Juszczyk, J. AU - Małkowski, P. AU - Pawłowska, M. AU - Simon, K. PY - 2017 DA - 2017// TI - Recommendations for the treatment of hepatitis C in 2017 JO - Clin Exp Hepatol VL - 3 UR - https://doi.org/10.5114/ceh.2017.67782 DO - 10.5114/ceh.2017.67782 ID - Halota2017 ER - TY - JOUR AU - Gonçales, F. L. AU - Moma, C. A. AU - Vigani, A. G. AU - Ngerami, A. F. AU - Gonçales, E. S. AU - Tozzo, R. PY - 2010 DA - 2010// TI - Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life JO - BMC Infect Dis VL - 10 UR - https://doi.org/10.1186/1471-2334-10-212 DO - 10.1186/1471-2334-10-212 ID - Gonçales2010 ER - TY - JOUR AU - Oze, T. AU - Hiramatsu, N. AU - Yakushijin, T. AU - Mochizuki, K. AU - Oshita, M. AU - Hagiwara, H. PY - 2011 DA - 2011// TI - Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan JO - J Gastroenterol VL - 46 UR - https://doi.org/10.1007/s00535-011-0409-7 DO - 10.1007/s00535-011-0409-7 ID - Oze2011 ER - TY - JOUR AU - Berg, T. AU - von Wagner, M. AU - Nasser, S. AU - Sarrazin, C. AU - Heintges, T. AU - Gerlach, T. PY - 2006 DA - 2006// TI - Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon- alfa-2a plus ribavirin JO - Gastroenterology VL - 130 UR - https://doi.org/10.1053/j.gastro.2006.02.015 DO - 10.1053/j.gastro.2006.02.015 ID - Berg2006 ER - TY - JOUR AU - Jacobson, I. AU - McHutchison, J. AU - Dusheiko, G. AU - Di Bisceglie, A. M. AU - Reddy, K. R. AU - Bzowej, N. H. PY - 2011 DA - 2011// TI - Telaprevir for previously untreated chronic hepatitis C virus infection JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1012912 DO - 10.1056/NEJMoa1012912 ID - Jacobson2011 ER - TY - JOUR AU - Poordad, F. AU - McCone, J. AU - Bacon, B. R. AU - Bruno, S. AU - Manns, M. P. AU - Sulkowski, M. S. PY - 2011 DA - 2011// TI - Boceprevir for untreated chronic HCV genotype 1 infection JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1010494 DO - 10.1056/NEJMoa1010494 ID - Poordad2011 ER - TY - JOUR AU - Zeuzem, S. AU - Andreone, P. AU - Pol, S. AU - Lawitz, E. AU - Diago, M. AU - Roberts, S. PY - 2011 DA - 2011// TI - Telaprevir for retreatment of HCV infection JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1013086 DO - 10.1056/NEJMoa1013086 ID - Zeuzem2011 ER - TY - JOUR AU - Bacon, B. R. AU - Gordon, S. C. AU - Lawitz, E. AU - Marcellin, P. AU - Vierling, J. M. AU - Zeuzem, S. PY - 2011 DA - 2011// TI - Boceprevir for previously treated chronic HCV genotype 1 infection JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1009482 DO - 10.1056/NEJMoa1009482 ID - Bacon2011 ER - TY - JOUR AU - Reddy, K. R. AU - Zeuzem, S. AU - Zoulim, F. AU - Weiland, O. AU - Horban, A. AU - Stanciu, C. PY - 2015 DA - 2015// TI - Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(14)71002-3 DO - 10.1016/S1473-3099(14)71002-3 ID - Reddy2015 ER - TY - JOUR AU - Cento, V. AU - Barbaliscia, S. AU - Lenci, I. AU - Ruggiero, T. AU - Magni, C. F. AU - Paolucci, S. PY - 2017 DA - 2017// TI - Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life JO - Clin Microbiol Infect VL - 23 UR - https://doi.org/10.1016/j.cmi.2017.04.005 DO - 10.1016/j.cmi.2017.04.005 ID - Cento2017 ER - TY - JOUR AU - Welzel, T. M. AU - Hinrichsen, H. AU - Sarrazin, C. AU - Buggisch, P. AU - Baumgarten, A. AU - Christensen, S. PY - 2017 DA - 2017// TI - Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German hepatitis C registry JO - J Viral Hepat VL - 24 UR - https://doi.org/10.1111/jvh.12708 DO - 10.1111/jvh.12708 ID - Welzel2017 ER - TY - JOUR AU - Calleja, J. L. AU - Crespo, J. AU - Rincón, D. AU - Ruiz-Antorán, B. AU - Fernandez, I. AU - Perelló, C. PY - 2017 DA - 2017// TI - Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCVgenotype 1 infection: results from a Spanish real-world cohort JO - J Hepatol VL - 66 UR - https://doi.org/10.1016/j.jhep.2017.01.028 DO - 10.1016/j.jhep.2017.01.028 ID - Calleja2017 ER - TY - JOUR AU - Dietz, J. AU - Susser, S. AU - Vermehren, J. AU - Peiffer, K. H. AU - Grammatikos, G. AU - Berger, A. PY - 2018 DA - 2018// TI - Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals JO - Gastroenterology VL - 154 UR - https://doi.org/10.1053/j.gastro.2017.11.007 DO - 10.1053/j.gastro.2017.11.007 ID - Dietz2018 ER - TY - JOUR AU - Di Maio, V. C. AU - Cento, V. AU - Lenci, I. AU - Aragri, M. AU - Rossi, P. AU - Barbaliscia, S. PY - 2017 DA - 2017// TI - Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies JO - Liver Int VL - 37 UR - https://doi.org/10.1111/liv.13327 DO - 10.1111/liv.13327 ID - Di Maio2017 ER - TY - JOUR AU - Kozuka, R. AU - Hai, H. AU - Motoyama, H. AU - Hagihara, A. AU - Fujii, H. AU - Uchida‐Kobayashi, S. AU - Morikawa, H. AU - Enomoto, M. AU - Murakami, Y. AU - Kawada, N. AU - Tamori, A. PY - 2018 DA - 2018// TI - The presence of multiple NS 5A RAS s is associated with the outcome of sofosbuvir and ledipasvir therapy in NS 5A inhibitor‐naïve patients with chronic HCV genotype 1b infection in a real‐world cohort JO - Journal of Viral Hepatitis VL - 25 UR - https://doi.org/10.1111/jvh.12850 DO - 10.1111/jvh.12850 ID - Kozuka2018 ER -